ARL3 and neoplasm: Strikingly, pharmacological intervention with tamoxifen revealed enhanced therapeutic responsiveness in ARL3‐deficient tumors, manifested in smaller lesion dimensions and lower tumor weights compared to tamoxifen‐treated controls (Figure 2L–N).